Apocyanin, NADPH oxidase inhibitor prevents lipopolysaccharide induced α-synuclein aggregation and ameliorates motor function deficits in rats: Possible role of biochemical and inflammatory alterations

Behavioural Brain Research

Volumn 296, Issue , 2016, Pages 177-190

  Sharma, Neha ^a   Kapoor, Monika ^a   Nehru, Bimla ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apocyanin; Cytokines; Lipopolysaccharide; NADPH oxidase complex; Neurodegeneration; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; APOCYANIN; CASPASE 3; CASPASE 9; CATALASE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACETOPHENONE DERIVATIVE; APOCYNIN; CYTOKINE; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CATALEPSY; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL BEHAVIORAL TEST; GLIA CELL; IMMUNOHISTOCHEMISTRY; LEWY BODY; LOCOMOTION; MALE; MICROGLIA; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TUNEL ASSAY; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; PARKINSON DISEASE, SECONDARY; SPRAGUE DAWLEY RAT;

ACETOPHENONES; ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; LIPOPOLYSACCHARIDES; MALE; NADPH OXIDASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84941966062     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.09.012     Document Type: Article

References (52)

1. Andersen J.K. Oxidative stress in neurodegeneration cause or consequence. Nat. Rev. Neurosci. 2004, 5:S18-S25.
2. Babior B.M. NADPH oxidase: an update. Blood 1999, 93:1464-1476.
3. Barreto G.E., Gonzalez J., Capani F., Morales L. Role of astrocytes in neurodegenerative diseases. Neurodegenerative Diseases-Processes Prevention Protection and Monitoring 2011, 485-486. Intechopen, ISBN, Available from . R.C.C. Chang (Ed.).
4. Block M.L., Zecca H.J.S. Microglia and inflammation mediated neurodegeneration multiple triggers with a common mechanism. Prog. Neurobiol. 2007, 76:77-98.
5. Bravo W.L.T., Jadhav V., Titova E., Zhang J.H., Tang J. NADPH oxidase inhibition improves neurological outcomes in surgically induced brain injury. Neurosci. Lett. 2007, 414(3):228-232.
6. Carter R.J. Curr. Protoc. Neurosci. 2001, 15:1-8.
7. Cookson M.R. Alpha-synuclein and neuronal cell death. Mol. Neurodegener. 2009, 4:9.
8. Costall B., Naylor R.J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 1974, 34(3):233-241.
9. Dauer W., Przedborski S. Parkinson's disease mechanisms and models. Neuron 2003, 39(6):889-909.
10. Ding Y. Impaired motor activity and motor learning function in rat with middle cerebral artery occlusion. Behav. Brain. Res. 1990, 132:29-36.
11. Ellman G.L. Tissue sulphydryl groups. Arch. Biochem. Biophy. 1959, 82:70-77.
12. Good P.F., Hsu A., Werner P., Perl D.P., Olanow C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 1998, 57:338-342.
13. Hald A., Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a casual link?. Exp. Neurol. 2005, 193(2):279-290.
14. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 1999, Oxford University Press, Oxford, UK.
15. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S210-S212.
16. Holmes W. In Recent advances in clinical pathology. London (Churchill) 1947.
17. Humason G.L. Basic Procedures-Animal Tissue Technique. Animal Tissue Techniques 1962, 130-132. W. H. Freeman & Co., San Francisco, Part-1.
18. Kono Y. Generation of superoxide radicals during auto oxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 1978, 186:189-195.
19. Kulkarni S.K. Handbook of Experimental Pharmacology 2002, Vallabh Prakashan, Delhi. 3rd ed.
20. Lee H.J., Kim C., Lee S.J. Alpha-synuclein stimulation of astrocytes potential role for neuroinflammation and neuroprotection. Oxid. Med. Cell Longev. 2010, 3(4):283-287.
21. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304(1):1-7.
22. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Follin's phenol reagent. J. Biol. Chem. 1951, 193:265-275.
23. Luck Methods of Enzymatic Analysis 2000, 885. Academic Press, New York. H.U. Bergmeyer (Ed.).
24. Lull M.E., Levesque S., Surace M.J., Block M.L. Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP (751) SL mice. PLoS One 2011, 6(5):e20153.
25. Marí M., Morales A., Colell A., García-Ruiz C., Fernández-Checa J.C. Mitochondrial glutathione a key survival antioxidant. Antioxid. Redox Signal. 2009, 11(11):2685-2700.
26. Martin H.L., Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J. 2009, 23(10):3263-3272.
27. McGeer P.L., McGeer E.G. Nsaids and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 2007, 28:639-647.
28. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
29. McGeer P.L., Yasojima K., McGeer E.G. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci. Lett. 2002, 326:67-69.
30. Moore D.J., West A.B., Dawson V.L., Ted M., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28:57-87.
31. Mosley E., Redegeld F.A., Bloksma N., Dunsmore K., Denenberg A., Wong H.R., NijKamp F.P., Engels F. Induction of HSP70 is dispensable for anti-inflammatory action of heat shock or NSAIDs in mast cells. Exp. Hematol. 2006, 34(4):414-423.
32. Nehru B., Verma R., Khanna P., Sharma S.K. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res. 2008, 1201:122-127.
33. Paxinos G.W., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Academic Press, Oxford, UK.
34. Pearse A.G.E. Histochemical, Theoretical and Applied 1968, Churchill Livingstone, London, pp 660. 3rd ed.
35. Rappold P.M., Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010, 7(4):413-423.
36. Ricci G., Volpi L., Pasquali L., Petrozzi L., Siciliano G. Astrocyte-neuron interactions in neurological disorders. J. Biol. Phys. 2009, 35(4):317-336.
37. Sharma N., Nehru B. Beneficial effect of vitamin E in rotenone induced model of PD: behavioural, neurochemical and biochemical study. Exp. Neurobiol. 2013, 22(3):214-223.
38. Sharma, N., Nehru, B., 2015. Apocyanin, a microglial NADPH oxidase inhibitor prevents dopaminergic neuronal degeneration in lipopolysaccharide induced Parkinson's disease model. doi: 10.1007/s12035-015-9267-2.
39. Sharma N., Nehru B. Characterization of the lipopolysaccharide induced model of Parkinson's disease: role of oxidative stress and neuroinflammation. Neurochem. Int. 2015, 87:92-105.
40. Surguchov A. Molecular and cellular biology of synucleins. Int. Rev. Cell Mol. Biol. 2008, 270:225-317.
41. Surguchov A. Synucleins: are they two-edged swords?. J. Neurosci. Res. 2013, 91(2):161-166.
42. Takalo M., Salminen A., Soininen H., Hiltunen M., Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am. J. Neurodegener. Dis. 2013, 2(1):1-14.
43. Tang X.N., Cairns B., Cairns N., Yenari M.A. Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience 2008, 154(2):556-562.
44. Thakur P., Nehru B. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease. Neuroscience 2013, 12(231):420-431.
45. Titova E., Ostrowski R.P., Sowers L.C., Zhang J.H., Tang J. Effects of apocynin and ethanol on intracerebral haemorrhage induced brain injury in rats. Clin. Exp. Pharmacol. Physiol. 2007, 34(9):845-850.
46. Wang Q., Tompkins K.D., Simonyi A., Korthuis R.J., Sun A.Y., Sun G.Y. Apocynin protects against global cerebral ischemiareperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res. 2006, 1090(1):182-189.
47. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 2003, 17:500-502.
48. Wu D.C., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
49. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. (Berl.) 1992, 84:100-104.
50. Zahler W.L., Cleland W.W. A specific and sensitive assay for disulphides. J. Biol. Chem. 1968, 243:716-719.
51. Zeevalk G.D., Razmpour R., Bernard L.P. Glutathione and Parkinson's disease is this the elephant in the room?. Biomed. Pharmacother. 2008, 62(4):236-249.
52. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J., Zhang J. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19(6):533-542.